Company performance
Current Price
as of Dec 27, 2024$38.96
P/E Ratio
14.62
Market Cap
$2.32B
Loading...
Description
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Metrics
Overview
- HQNewark, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerPTGX
- Price$38.96-1.39%
Trading Information
- Market cap$2.32B
- Float94.52%
- Average Daily Volume (1m)690,431
- Average Daily Volume (3m)663,540
- EPS$2.82
Company
- Revenue$323.79M
- Rev growth (1yr)N/A
- Net income-$33.21M
- Gross margin86.16%
- EBITDA margin-872.86%
- EBITDA-$40.81M
- EV$2.32B
- EV/Revenue7.17
- P/E14.62
- P/S7.43
- P/B4.36
Documents
SEC Filings
Factset Street Account